Dr. Aykut Uren (Georgetown University, Washington DC, USA)

"Targeting protein-protein interactions as experimental and therapeutic tools"

Dr. √úren investigates molecular mechanisms of cancer pathogenesis in pediatric sarcomas. His team discovered several first in class small molecule inhibitors for key target proteins, one of which is in Phase 1 clinical trial. His approach has been to identify compounds that can directly bind to the target protein by surface plasmon resonance and then perform a secondary screen to select compounds that inhibit the function of the target protein. Disease focuses have been on Ewing sarcoma, osteosarcoma and rhabdomyosarcoma that contain the target protein EWS-FLI1, ezrin, CD and PAX3-FOXO1.

Published Mar. 4, 2019 3:56 PM - Last modified Mar. 4, 2019 4:29 PM